Dynamic Cell Therapies Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Out of Business

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Out of Business

Dynamic Cell Therapies General Information

Description

Developer of next-generation CAR (Chimeric Antigen Receptor) T-cell therapies designed for the treatment of liquid and solid tumors. The company develops transformative CAR T cell technology for multiplexing, titration, and modularity and treats relapsed or refractory cancers, enabling healthcare providers to focus on improving the safety, efficacy, durability, and accessibility of T-cell therapy by engineering life-saving constructs to alleviate patient suffering.

Contact Information

Formerly Known As
Raqia Therapeutics
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 177 Arlington Street
  • Medford, MA 02155
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 177 Arlington Street
  • Medford, MA 02155
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dynamic Cell Therapies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 28-Apr-2026 Completed Out of Business
3. Seed Round 11-Jul-2024 Completed Generating Revenue
2. Seed Round 01-Nov-2022 $2M $5M Completed Pre-Clinical Trials
1. Seed Round 26-Feb-2021 $3M $3M Completed Startup
To view Dynamic Cell Therapies’s complete valuation and funding history, request access »

Dynamic Cell Therapies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-2
Seed
To view Dynamic Cell Therapies’s complete cap table history, request access »

Dynamic Cell Therapies Patents

Dynamic Cell Therapies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025255266-A1 Engineered polypeptides for immune cell activation Pending 05-Jun-2024
WO-2025255266-A8 Engineered polypeptides for immune cell activation Pending 05-Jun-2024
WO-2025255267-A1 Engineered receptors for activation of regulatory t-cells Pending 05-Jun-2024
EP-4630446-A1 Engineered switches for immune cell activity and methods of use thereof Pending 06-Dec-2022
US-20250297022-A1 Engineered switches for immune cell activity and methods of use thereof Pending 06-Dec-2022 C07K16/2878
To view Dynamic Cell Therapies’s complete patent history, request access »

Dynamic Cell Therapies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dynamic Cell Therapies FAQs

  • When was Dynamic Cell Therapies founded?

    Dynamic Cell Therapies was founded in 2016.

  • Where is Dynamic Cell Therapies headquartered?

    Dynamic Cell Therapies is headquartered in Medford, MA.

  • What is the size of Dynamic Cell Therapies?

    Dynamic Cell Therapies has 16 total employees.

  • What industry is Dynamic Cell Therapies in?

    Dynamic Cell Therapies’s primary industry is Drug Discovery.

  • Is Dynamic Cell Therapies a private or public company?

    Dynamic Cell Therapies is a Private company.

  • What is Dynamic Cell Therapies’s current revenue?

    The current revenue for Dynamic Cell Therapies is .

  • How much funding has Dynamic Cell Therapies raised over time?

    Dynamic Cell Therapies has raised $6M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process